Carmen González-Vela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen González-Vela has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Elísabet López-Sundh
Department of Dermatology Hospital Universitario Marqués de Valdecilla Santander Spain
1 shared publication - Eli Louis Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication - Francisco Gomez de la Fuente
Servicio de Medicina Nuclear, Hospital U.M. Valdecilla, Universidad de Cantabria, IDIVAL, 39008 Santander, Spain
1 shared publication - Jose Antonio Riancho
Servicio de Medicina Interna, Hospital U.M. Valdecilla, Santander, Spain; Universidad de Cantabria, Santander, Spain; Instituto de Investigación M. Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain, Spain
1 shared publication - Jose Luis Hernandez
Department of Internal Medicine and Psychiatry, Hospital Universitario Marqués de Valdecilla-IDIVAL, Immunopathology Group, University of Cantabria, Santander, Spain
1 shared publication - Marcos Antonio González-López
Dermatology Department, Department of Medicine and Psychiatry, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain
1 shared publication
Latest Publications
- Open Access
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Open AccessErdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.